Package advice pralsetinib (Gavreto®) for the treatment of non-small cell lung carcinoma (NSCLC)
The National Health Care Insititute has completed its assessment whether pralsetinib (Gavreto®) can be included in the basic health care package for the treatment of adult patients with non-small cell lung carcinoma (NSCLC). The National Health Care Institute advises the Minister to not include pralsetinib in the health insurance package for the specified indication, because pralsetinib does not meet the established medical science and medical practice due to insufficient data.
Registered indication
Reimbursement is requested for the treatment of adult patients with rearranged during transfection (RET)-fusion-positive advanced non-small cell lung carcinoma (NSCLC), who have not previously been treated with a RET inhibitor.
The National Health Care Institute's advice
The National Health Care Institute advises the Minister to not include pralsetinib in the health insurance package for the specified indication. Despite the fact that the data is promising, pralsetinib does not meet the established medical science and medical practice due to insufficient data.